Objective This study was designed to determine the combined therapeutic effects of artesunate and carboplatin in treating retinoblastoma, compared with carboplatin alone, artesunate alone and control groups after having established newborn mice retinoblastoma model successfully. Methods (1)The cell line RBY-79 in a single-cell suspension was implanted into the right vitreous body of newborn littermates to set up a retinoblastoma xenograft model.(2)Mice bearing palpable tumors were randomly divided into four independent groups after all retinoblastoma xenograft models had been established, respectively, combined group, carboplatin group, ART group and control group. Our aims were to observe and compare the tumor size and survival time of retinoblastoma newborn mice in different groups. Results (1)Retinoblastoma xenograft models of newborn mice were successfully established and a consistent and statistically significant difference was found in the tumor weight between the right and left eyes (P<0.0001).(2)①The tumor weights in combined group, carboplatin group and ART group were significantly less than that in control (P<0.0001,P<0.0001,P=0.0015), at the same time, the survival time in these the former two groups were longer (P=0.0253,P=0.0253), that in ART group was not longer(P=0.8722). ②The tumor weights in combined group, carboplatin group were significantly less than that in ART group (P=0.0084, P=0.0015), and the survival time in the two groups were longer (P=0.0240, P=0.0239). ③The tumor weight in combined group was significantly no less than that in carboplatin group and the survival time was not longer (P=0.7980, P=1.0000). Conclusions In our study, we can find that combined treatment, carboplatin and ART can significantly inhibit the growth of retinoblastoma in vivo. However, ART does not significantly enhance the antitumor effects of carboplatin during the treatment.
Key words
retinoblastoma /
artesunate /
carboplatin /
combined treatment
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Guillermo Chantada, Paula Schaiquevich. Management of Retinoblastoma in Children: Current Status[J]. J Pediatric Drugs, 2015, 17(3):185-198.
[2] Francesco Pichi, Andrea Lembo, Mariacarla, et al. Bilateral retinoblastoma: clinical presentation, management and treatment[J]. International Ophthalmology, 2013, 33(5):589-593.
[3] Murphree A L, Villablanca J G, Deegan W F, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma[J].Arch Ophthalmol-chic, 1996, 114(11):1348-1356.
[4] Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.[J]. Arch Ophthalmol, 2011, 129(11):1422-1427.
[5] Varan A, Kiratli H, Aydin B, et al. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide[J]. Pediat Hematol Onc, 2012, 29(6):529-537.
[6] Veal G J, Boddy A V. Carboplatin dosing in infants with retinoblastoma: A case for therapeutic drug monitoring[J]. J Clin Oncol, 2012, 30(27):3424-3029.
[7] Qaddoumi I, Bass J K, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma[J]. J Clin Oncol, 2012, 30(10):1034-1041.
[8] Rajkumar Venkatramani MD, Rima Fuad Jubran MD. Retinoblastoma: Intravenous Chemotherapy[J] Clinical Ophthamic Oncology, 2015, 126(6):119-127.
[9] Antoneli C B, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: A 13-year experience[J]. Cancer, 2003, 98(6):1292-1298.
[10] Baroni LV, Sampor C, Solernou V, et al. Anterior segment invasion in retinoblastoma: is it a risk factor for extraocular relapse?[J]. J Pediatr Hematol Oncol, 2014, 36(8):509-512.
[11] Efferth T, Giaisi M, Merling A, et al. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells[J]. PLoS One, 2007, 2(8):e693.
[12] Zhao F, Wang H, Kunda P, et al. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71[J]. Oncol Rep, 2013, 30(3):1473-1482.
[13] Cruet-Hennequart S, Villalan S, Kaczmarczyk A, et al. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells[J]. Cell Cycle, 2009, 10(18):3043-3054.
[14] Xiong X, Sui M, Fan W et al. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy[J]. Cancer Biol Ther, 2007, 6(7):1067.
PDF(2396 KB)
